Drug | Target | Mechanism of Action | Condition Used | Adverse Effects |
---|---|---|---|---|
Ipilimumab, tremelimumab | CTLA-4 | Anti-CTLA-4 selectively blocking CTLA-4 | Metastatic melanoma, several types of advanced malignancy | Immune-related AEs such as hypophysitis, colitis, uveitis, dermatitis, and arthritis |
Aducanumab | Amyloid β aggregates, including soluble oligomers and insoluble fibrils | Decrease CNS amyloid burden | MCI and mild Alzheimer disease | ARIA |
Adalimumab | TNF-α | Blocks TNF-α interaction with p55 and p75 cell surface TNF receptors | RA, PsA, AS, IBD, JIA, and HS | Neurologic AEs including demyelinating diseases, ON, CIDPN, MNM, and GB |
NTZ | α4β1 Integrin | Blocks entry of T cells into the CNS | Multiple sclerosis (RRMS) | PML, PML-IRIS, NTZ rebound |
Note:—ON indicates optic neuritis; CIDPN, chronic inflammatory demyelinating polyneuropathy; MNN, mononeuritis multiplex; GB, Guillain-Barré syndrome; RRMS, relapsing-remitting MS; AS, ankylosing spondylitis; MCI, mild cognitive impairment; RA, rheumatoid arthritis; PsA, psoriatic arthritis; IBD, inflammatory bowel diseases; JIA, juvenile idiopathic arthritis, HS, hidradenitis suppurativa.